Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Using the A/T/N Framework to Examine Driving in Preclinical AD.
Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC
Geriatrics (Basel). 2018 Jun; 3(2)pii: 23. doi: 10.3390/geriatrics3020023.

PMID:
    29805967
    [PubMed]
Related citations


AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR
Mol Neurodegener. 2018 May 15; 13(1)22. doi: 10.1186/s13024-018-0256-6.

PMID:
    29764453
    [PubMed - in process]
Related citations


White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.
Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM, Dominantly Inherited Alzheimer Network.
PLoS One. 2018; 13(5)e0195838. doi: 10.1371/journal.pone.0195838.

PMID:
    29742105
    [PubMed - in process]
Related citations


Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.
Patel TK, Holtzman DM
J Exp Med. 2018 May 7; 215(5)1267-1268. doi: 10.1084/jem.20180494.

PMID:
    29685951
    [PubMed - in process]
Related citations


Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.
Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA
Brain. 2018 Jun 1; 141(6)1828-1839. doi: 10.1093/brain/awy103.

PMID:
    29672664
    [PubMed - in process]
Related citations


NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors.
Alzheimers Dement. 2018 Apr; 14(4)535-562. doi: 10.1016/j.jalz.2018.02.018.

PMID:
    29653606
    [PubMed - in process]
Related citations


Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.
Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM
J Clin Invest. 2018 May 1; 128(5)2144-2155. doi: 10.1172/JCI96429.

PMID:
    29600961
    [PubMed - in process]
Related citations


Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.
Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM, ADNI.
Alzheimers Dement. 2018 Mar 23; pii: S1552-5260(18)30031-1. doi: 10.1016/j.jalz.2018.01.012.

PMID:
    29580670
    [PubMed - as supplied by publisher]
Related citations


Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM
Alzheimers Dement. 2018 Mar 2; pii: S1552-5260(18)30039-6. doi: 10.1016/j.jalz.2018.01.013.

PMID:
    29501462
    [PubMed - as supplied by publisher]
Related citations


ApoE facilitates the microglial response to amyloid plaque pathology.
Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM
J Exp Med. 2018 Apr 2; 215(4)1047-1058. doi: 10.1084/jem.20171265.

PMID:
    29483128
    [PubMed - in process]
Related citations


Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS
Lancet Neurol. 2018 Mar; 17(3)241-250. doi: 10.1016/S1474-4422(18)30028-0.

PMID:
    29397305
    [PubMed - in process]
Related citations


Regulation of amyloid-β dynamics and pathology by the circadian clock.
Kress GJ, Liao F, Dimitry J, Cedeno MR, FitzGerald GA, Holtzman DM, Musiek ES
J Exp Med. 2018 Apr 2; 215(4)1059-1068. doi: 10.1084/jem.20172347.

PMID:
    29382695
    [PubMed - in process]
Related citations


Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.
Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju YS
JAMA Neurol. 2018 May 1; 75(5)582-590. doi: 10.1001/jamaneurol.2017.4719.

PMID:
    29379963
    [PubMed - in process]
Related citations


Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM
Nat Rev Neurol. 2018 Mar; 14(3)168-181. doi: 10.1038/nrneurol.2017.185.

PMID:
    29377010
    [PubMed - in process]
Related citations


Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.
Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM
Alzheimers Dement. 2018 May; 14(5)610-616. doi: 10.1016/j.jalz.2017.11.011.

PMID:
    29328928
    [PubMed - in process]
Related citations


Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.
Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T, Holtzman DM
Neuron. 2017 Dec 6; 96(5)1013-1023.e4. doi: 10.1016/j.neuron.2017.11.014.

PMID:
    29216448
    [PubMed - indexed for MEDLINE]
Related citations


Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.
West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H, Mendonca N, Holtzman DM
J Prev Alzheimers Dis. 2017; 4(4)236-241. doi: 10.14283/jpad.2017.36.

PMID:
    29181488
    [PubMed - in process]
Related citations


Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury.
Movsas TZ, Weiner RL, Greenberg MB, Holtzman DM, Galindo R
Front Pediatr. 2017; 5232. doi: 10.3389/fped.2017.00232.

PMID:
    29164084
    [PubMed]
Related citations


Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM
Neurology. 2017 Dec 5; 89(23)2381-2391. doi: 10.1212/WNL.0000000000004717.

PMID:
    29117955
    [PubMed - indexed for MEDLINE]
Related citations


Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, Parent AT, Holtzman DM, Thinakaran G
Proc Natl Acad Sci U S A. 2017 Nov 7; 114(45)E9665-E9674. doi: 10.1073/pnas.1708568114.

PMID:
    29078331
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: C2N Diagnostics

Royalties: > $250,000

Equity: Yes

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2018


Company Name: Denali

Royalties: $1 - $9,999

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.